ARTICLE | Clinical News
Copaxone glatiramer acetate: Marketed
March 12, 2001 8:00 AM UTC
TEVA published in the Annals of Neurology data from a previously reported study of 239 patients showing that Copaxone gave a 29 percent reduction in the trial’s primary end point of total number of en...